ThromboGenics Initiates Phase 2 Clinical Study Evaluating anti-PlGF (THR-317) in combination with anti-VEGF (ranibizumab) for treatment of Diabetic Macular Edema (DME)

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Suma Ramadas, PhD
Medical Affairs

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access